The state of Missouri currently has 22 active clinical trials seeking participants for Non-Small Cell Lung Cancer research studies. These trials are conducted in various cities, including Saint Louis, Kansas City, St. Louis and Springfield.
Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer
Recruiting
Study of MGY825 single agent in adult patients with advanced non-small cell lung cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/23/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Non-small Cell Lung Cancer
A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer
Recruiting
This trial will evaluate the efficacy and safety of various therapies in patients with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated non-small cell lung cancer (NSCLC) tumors that meet protocol-specified biomarker criteria
Gender:
All
Ages:
18 years and above
Trial Updated:
02/21/2024
Locations: University of Missouri Health Care; Ellis Fischel Cancer Center, Columbia, Missouri +2 locations
Conditions: Non-small Cell Lung Cancer
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
Recruiting
Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of furmonertinib at 2 dose levels (160 mg once daily [QD] and 240 mg QD) compared to platinum-based chemotherapy in previously untreated patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations. A target of approximately 375 patients will be randomized in a 1:1:1 ratio to treatment with furmonert... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: Arrivent Investigative Site, Bolivar, Missouri +3 locations
Conditions: Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
Recruiting
This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic carcinoma expressing EGFR.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
02/20/2024
Locations: Washington University, Saint Louis, Missouri
Conditions: Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Colorectal Carcinoma
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
Recruiting
This is a first-in-human, open-label, nonrandomized, four-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX-105 and INBRX-105 in combination with Pembrolizumab. INBRX-105, a next generation bispecific antibody, targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor. INBRX-105 provides localized conditional T-cell co-stimulation through 4-1BB agonism.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: Washington University, Saint Louis, Missouri
Conditions: Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Gastric Adenocarcinoma, Renal Cell Carcinoma, Esophageal Adenocarcinoma, Nasopharyngeal Carcinoma, Oropharyngeal Carcinoma
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Recruiting
This is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of CHS-388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in patients with solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/16/2024
Locations: Washington University School of Medicine - St. Louis, Saint Louis, Missouri
Conditions: Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer
Recruiting
Since anti-PD1, anti-TIGIT, and A2R antagonists have complementary mechanisms of action, and the latter two have shown synergism in combination with antibodies against PD-1, othis study aims to evaluate the efficacy and tolerability of the triplet combination of zimberelimab, domvanalimab, and etrumadenant in patients with non-small cell lung cancer previously treated with immune checkpoint blockade therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/09/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Non Small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer
GEMINI-NSCLC: NSCLC Biomarker Study
Recruiting
Non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: Oncology Hematology Associates, Springfield, Missouri
Conditions: Non-Small Cell Lung Cancer
Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
Recruiting
BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of BDTX-1535. The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2)... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/02/2024
Locations: Siteman Cancer Center, Saint Louis, Missouri
Conditions: Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, NSCLC, Advanced Lung Carcinoma, Epidermal Growth Factor Receptor C797S, Epidermal Growth Factor Receptor G719X, EGF-R Positive Non-Small Cell Lung Cancer, EGFR-TKI Resistant Mutation
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Recruiting
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/02/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor, Metastatic Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Gastroesophageal-junction Cancer, WNT Pathway, β-catenin, Beta-catenin, Adenomatous Polyposis Coli, APC
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Recruiting
This is a Phase 1, open-label, first-in-human study of CTX-471 administered as a monotherapy or in combination with pembrolizumab in patients with metastatic or locally advanced malignancies that have progressed while receiving an approved PD-1 or PD-L1 inhibitor. The study will be conducted in 2 treatment arms (Monotherapy Arm 1 and Combination Arm 2). Each arm will have two parts: Part 1 Dose Escalation and Part 2 Dose Expansion.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: Washington University School of Medicine, Siteman Cancer Center, Saint Louis, Missouri
Conditions: Locally Advanced Solid Tumor, Metastatic Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Mesothelioma, Melanoma, Head and Neck Cancer
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Recruiting
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.
Gender:
All
Ages:
12 years and above
Trial Updated:
01/17/2024
Locations: Washington University Medical School, Saint Louis, Missouri
Conditions: Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor